Stevanato Group SpA (STVN) revenue breakdown
By segment, Biopharmaceutical and Diagnostic Solutions is the largest at 88% of fiscal 2025 revenue, growing 13% a year over 5 years.
By product, High-Value Solutions is the largest at 46% of fiscal 2025 revenue, growing 30% a year over 5 years.
Revenue by segment
Fiscal years, as Stevanato Group SpA reports them in its 10-K filings; fiscal 2025 total $1.2B.
| Segments | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Biopharmaceutical and Diagnostic Solutions | $565M | $694M | $800M | $879M | $934M | $1.0B | 88% |
| Engineering | $97M | $150M | $184M | $206M | $170M | $148M | 12% |
Revenue by product
Fiscal years, as Stevanato Group SpA reports them in its 10-K filings; fiscal 2025 total $1.2B.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| High-Value Solutions | $146M | $208M | $293M | $366M | $422M | $546M | 46% |
| Other Containment and Delivery Solutions | $419M | $486M | $506M | $513M | $511M | $492M | 41% |
| Revenue from Engineering | $97M | $150M | $184M | $206M | $170M | $148M | 12% |
Revenue by region
Fiscal years, as Stevanato Group SpA reports them in its 10-K filings; fiscal 2025 total $1.2B.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| EMEA | $398M | $493M | $600M | $634M | $668M | $690M | 58% |
| North America | $175M | $207M | $251M | $318M | $309M | $362M | 31% |
| APAC | $67M | $118M | $100M | $103M | $96M | $101M | 9% |
| South America | $22M | $26M | $33M | $31M | $31M | $32M | 3% |
Questions
Where does Stevanato Group SpA make its money?
In fiscal 2025, by segment: Biopharmaceutical and Diagnostic Solutions $1.0B, Engineering $148M.
From Stevanato Group SpA's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.